2-<(tetrahydro-2-pyranyl)oxy>-1-propanol | 3539-39-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: 2-<(tetrahydro-2-pyranyl)oxy>-1-propanol
• 英文别名: 2-((tetrahydro-2H-pyran-2-yl)oxy)propan-1-ol；2-(tetrahydro-pyran-2-yloxy)-propan-1-ol；2-(tetrahydro-2-pyranyloxy)propanol；(R)-2-(tetrahydro-pyran-2-yloxy)-propan-1-ol；2-O-(tetra-hydropyran-2-yl)propane-1,2-diol；(S)-2-(2-tetrahydropyranyloxy)-1-propanol；1-Propanol, 2-[(tetrahydro-2H-pyran-2-yl)oxy]-；2-(oxan-2-yloxy)propan-1-ol
• CAS: 3539-39-7
• 化学式: C₈H₁₆O₃
• 分子量: 160.213
• InChiKey: MKWQCXIXWYWZBA-UHFFFAOYSA-N

物化性质

• 沸点：
  263.1±30.0 °C(Predicted)
• 密度：
  1.04±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2932999099

反应信息

• 作为反应物：
  描述：

  2-<(tetrahydro-2-pyranyl)oxy>-1-propanol 在 草酰氯 、 二甲基亚砜 、 三乙胺 作用下， 生成 2-((tetrahydro-2H-pyran-2-yl)oxy)propanal
  参考文献：
  名称：

  格氏试剂对铁催化的γ，δ-环氧-α，β-不饱和酯和酰胺的区域和立体选择性取代

  摘要：

  当在10−24 mol％FeCl 2存在下用2当量的Grignard试剂处理γ，δ-环氧-α，β-不饱和酯或酰胺时，发生了用Grignard试剂对环氧部分进行区域和立体选择性取代仅以高收率得到δ-羟基-γ-烷基或芳基-α，β-不饱和酯或酰胺。

  DOI：

  10.1021/ol100022w
• 作为产物：
  描述：

  2-[(四氢吡喃-2-基)氧基]丙酸乙酯 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 反应 2.5h， 以97%的产率得到2-<(tetrahydro-2-pyranyl)oxy>-1-propanol
  参考文献：
  名称：

  Au-catalyzed intramolecular hydroalkoxylation of gem-difluorinated alkynols

  摘要：

  The intramolecular hydroalkoxylation of gem-difluorinated alkynols was found possible under Au catalysis, allowing for the preparation of a series of fluorinated heterocycles. The nature of the solvent was found to be especially critical in the cyclization of gem-difluorohomopropargylic alcohols as it dictated whether the resulting 2,3-dihydrofuran underwent subsequent aromatization to the corresponding furan or not.

  DOI：

  10.1016/j.jfluchem.2018.09.009

文献信息

• [EN] BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS<br/>[FR] DÉRIVÉS BIARYLE EN TANT QU'INHIBITEURS D'INTERACTION PROTÉINE-PROTÉINE YAP/TAZ-TEAD
  申请人：NOVARTIS AG

  公开号：WO2021186324A1

  公开（公告）日：2021-09-23

  The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; (I) a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.

  本发明提供了化合物(I)或其药学上可接受的盐；(I)制造所述化合物的方法及其治疗用途。本发明还提供了药理活性剂的组合物和包括所述化合物的药物组合。
• SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS
  申请人：Mjalli Adnan M.M.

  公开号：US20110237570A1

  公开（公告）日：2011-09-29

  The present invention provides substituted imidazo[1,2-b]pyridazine derivatives, pharmaceutically acceptable salts thereof, and tautomers of any of the foregoing, where such compounds inhibit β-site amyloid precursor protein-cleaving enzyme (BACE), which may be useful in the treatment of diseases in which BACE is involved, such as Alzheimer's disease. The invention also provides pharmaceutical compositions comprising any of these compounds and the use of any of these compounds and compositions in the treatment of diseases, disorders, or conditions in which BACE is involved.

  本发明提供了替代的咪唑并[1,2-b]吡啶嗪衍生物，其药学上可接受的盐，以及上述任何一种的互变异构体，这些化合物抑制β-淀粉样前体蛋白裂解酶（BACE），这可能对治疗涉及BACE的疾病，如阿尔茨海默病，具有益处。本发明还提供了包括任何这些化合物的药物组合物以及在治疗涉及BACE的疾病、疾患或症状中使用任何这些化合物和组合物的用途。
• Control of Phase-transition Behavior and Polymerization Capability by Methyl Addition to Dialkyl Fumarates Bearing Cyanobiphenyl Mesogens
  作者：Nozomu Fujii、Tsuyoshi Michinobu、Kiyotaka Shigehara

  DOI：10.1246/cl.2007.1052

  日期：2007.8.5

  Addition of methyl groups to dialkyl fumarates bearing two cyanobiphenyl mesogens dramatically changed the phase-transition behavior and polymerization capability. No mesophase appeared and radical polymerization did not proceed in the absence of the branched methyl groups, whereas well-defined liquid-crystal phases were observed in the ambient temperature range and high molecular weight polymers were obtained in the presence of the branched methyl groups. An increase in the number of the attached methyl groups decreases the liquid crystalline temperature width as well as the molecular weight of the resulting polymers.

  向含有两个氰基联苯介晶基团的二烷基富马酸盐中加入甲基，显著改变了其相变行为和聚合能力。在缺乏支链甲基的情况下，无法出现介晶相，并且自由基聚合也不能进行；而在存在支链甲基的情况下，在环境温度范围内观察到了明确定义的液晶相，并获得了高分子量的聚合物。随着所附甲基数量的增加，液晶相的温度宽度以及所得聚合物的分子量都逐渐下降。
• [EN] PYRIDAZINONES AS PARP7 INHIBITORS<br/>[FR] PYRIDAZINONES UTILISÉES EN TANT QU'INHIBITEURS DE PARP7
  申请人：RIBON THERAPEUTICS INC

  公开号：WO2021087025A1

  公开（公告）日：2021-05-06

  The present invention relates to pyridazinones and related compounds which are inhibitors of PARP7 and are useful in the treatment of cancer.

  本发明涉及吡啶并嗪酮和相关化合物，其为PARP7的抑制剂，可用于癌症治疗。
• Propoxybenzene derivatives and process for preparing the same
  申请人：Daiichi Pharmaceutical Co., Ltd.

  公开号：US05136059A1

  公开（公告）日：1992-08-04

  Propoxybenzene derivatives represented by the following formula ##STR1## wherein Ra represents a nitro group, an amino group which may have a protecting group or an --NHCH.dbd.C(COO--C.sub.1-6 -Alkyl).sub.2 group, Rb represents a hydrogen atom, a protecting group for the hydroxyl group or a substituted sulfonyl group and Xa and Xb, which may be the same or different, each represents a halogen atom, and processes for preparation thereof are disclosed. These derivatives are useful in preparing antibacterial agents.

  该专利涉及一种以以下结构式表示的丙氧基苯衍生物，其中Ra代表一个硝基，一个可能带有保护基的氨基或一个--NHCH.dbd.C(COO--C.sub.1-6 -Alkyl).sub.2基团，Rb代表一个氢原子，一个羟基的保护基或一个取代磺酰基，Xa和Xb分别代表卤原子，可以相同也可以不同。揭示了制备这些衍生物的方法。这些衍生物在制备抗菌剂方面非常有用。